There are actually two different sites to read about the SPORE projects. On the other one they specifically mention Merck and Pembrolizumab (Keytruda), on the other one they do not.
Always interesting to see what is not mentioned, like Poly ICLC. Seems the effort here is to focus the combo message on the major players even though more is known. Of course if survival at 10 years goes from over 50% to closer to 100% ie “tumor elimination” then there is at least a decent pretext for doing so. Best wishes.
Correct, in all documentation related to these trials it is always about the category of drug, not the company that might provide the drug or their sponsorship.